ev3 Onyx: The Sales Target Reached Into the Operating Room

The ev3 Onyx guilty plea agreement concerned a sales program that pushed a brain embolization device into unapproved procedures elsewhere in the body. The Justice Department’s announcement of the criminal information and plea agreement described sales incentives in the criminal information and instructions to surgeons in the plea agreement. For someone who knew the training, the territory targets or the instructions given during surgery, the connection was concrete: the company rewarded the sales its people were teaching physicians to make possible.

On December 4, 2018, the department announced that ev3 had agreed to plead guilty to a corporate misdemeanor involving the distribution of adulterated Onyx under the Food, Drug and Cosmetic Act. The charge concerned how the company distributed and promoted the device beyond its approved use.

What Onyx Was Approved to Do

Onyx Liquid Embolic System was approved for the presurgical treatment of brain arteriovenous malformations. It is a liquid introduced through a catheter that forms a solid mass and blocks blood flow. In its account of the separate civil Onyx case, the federal district court dated that approval to July 2005.

According to the plea agreement described by the Justice Department, ev3’s representatives encouraged surgeons to use large quantities of Onyx outside the brain from 2005 to 2009. The department described those uses as unproven and potentially dangerous.

The plea agreement described quantities far larger than those used in the brain. Expanding into another procedure could mean selling substantially more product for that procedure.

The Operating Room Became a Sales Channel

According to the plea agreement, ev3 representatives sometimes attended surgical procedures and gave surgeons explicit instructions for using Onyx outside the brain. The sales message reached the point where the product was being used on a patient.

A Senate Finance Committee staff report on the implant supply chain, published in 2011, described manufacturers selling through employees and independent representatives. Their work could include ordering and delivery, stocking and restocking, sterilization, supplying instrumentation and assisting surgeons in the operating room.

Those responsibilities put the commercial side of a device company close to the clinical decision. The Onyx plea agreement described that proximity becoming the means of delivering instructions for unapproved procedures.

The distinction between a sales presentation and an instruction during surgery matters to an insider’s account. A representative may remember which procedure was discussed, which physician received the instruction and how much product was involved. A hospital employee may remember the same event from the other side of the room. Those accounts can connect a commercial message to a particular use of the device.

FDA Asked for a Study and the Sales Push Continued

According to the plea agreement, Food and Drug Administration officials raised specific concerns about the safety of using Onyx outside the brain at a meeting with ev3 executives in 2008. They told the executives that a study would be required to obtain approval for those uses and establish that the benefits outweighed the risks.

The sales force continued promoting the uses after that meeting. The department described representatives attending procedures and giving instructions instead of ev3 conducting the study needed to establish safety and effectiveness for the broader use.

The safety concern had reached executives. The Food and Drug Administration had identified the evidence it wanted. Yet the commercial effort continued into operating rooms, exposing patients to uses the department described as unproven and potentially dangerous.

For a regulatory or clinical employee, the meeting and the sales activity belong in the same account. What management learned about the device’s limitations matters alongside what representatives were subsequently taught to tell physicians. The Food and Drug Administration asked for evidence supporting the broader use. The company continued supplying instructions for performing it.

Sales Quotas Pointed Beyond the Approved Market

The criminal information charged that ev3 management used sales quotas and bonuses to encourage unapproved Onyx sales. Management also trained the sales force to instruct physicians in those uses. The incentive and the instruction came from the company.

A separate civil whistleblower case put a territory’s sales target beside its approved-use market. The district court’s decision recounting the whistleblower’s allegations described an internal assessment for 2009: the territory’s maximum revenue from approved uses was allegedly $506,250, while the assigned Onyx quota was $1,509,533.

The whistleblower alleged that the lower figure assumed winning all the territory’s business for the approved procedure. The target still reached well beyond that market. That comparison makes the allegation more tangible than a general complaint about pressure to sell.

The same civil case described a proposed complaint alleging that ev3 supplied Onyx to hospitals where a trained physician had admitting privileges, including facilities without surgeons whose practices called for the approved use. It also alleged that ev3 paid physicians to train other physicians, sometimes in unapproved uses.

The allegations show why territory forecasts, training arrangements and account access belong together when examining a device sales program. A forecast describes the business management believes is available. A quota describes the business it expects the representative to produce. Training can show how the company expected the representative to close the distance.

The Acquisitions Came After the Conduct

The Justice Department said Covidien acquired ev3 in 2010, after the conduct covered by the plea agreement. Medtronic acquired Covidien in 2015. The department expressly stated that Medtronic played no role in the criminal conduct.

Later ownership explains why additional company names appear in the announcement. It does not move the earlier conduct to the later owner.

Solitaire’s Civil Settlement Was a Different Case

Covidien’s separate Solitaire settlement, announced in the same release, concerned alleged kickbacks involving a different device.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

Yes. A former ev3 sales employee brought a qui tam case under the False Claims Act involving Onyx. According to the district court’s account, his proposed complaint alleged that ev3 caused false reimbursement claims and described Onyx sales targets and training that promoted unapproved uses.

The practical question for a civil device case is how the manufacturer’s conduct affected the care and the claim for payment. We examine the sales instruction, the procedure it influenced and what the hospital or physician billed.

A 2020 review in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, explains that a bill can be false even when the patient received care: the provider may have lied about meeting requirements for payment.

What Kind of Proof Is Needed to Be a Whistleblower?

In a device sales case, useful proof connects what the manufacturer encouraged, what happened during treatment and what the government was asked to pay. An insider’s knowledge of a quota, training session or operating-room instruction can help explain a connection that billing data alone would miss.

On the company side, the Onyx allegations make the relevant decisions concrete: who set the target, how bonuses rewarded sales, what the sales force learned about unapproved uses and what executives knew after meeting with the Food and Drug Administration.

On the hospital side, there may be a record of who attended the procedure. The Association of periOperative Registered Nurses’ position statement reaffirmed in 2025 calls for documenting an industry representative’s name, company and time in the room in the intraoperative nursing record, according to hospital policy. It also identifies potential influence on physicians’ product selection as a concern.

We work with the insider to understand how the company’s instructions, the hospital’s records and the claim for payment fit together.

A sales employee, clinical specialist, regulatory employee or hospital staff member may see a different part of this sequence. The value of that perspective is knowing what the paperwork meant in practice: why that physician was approached, why that use was promoted or why the target could not be met within the market the company had identified.

How Much Is a Whistleblower Claim Worth?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What the Sales Target Required

If you saw a device sales target turn into instructions in the operating room, speak to one of our Whistleblower Experts about the instructions you saw. We bring in medical device whistleblower lawyers and build your strongest case around your knowledge of the product, the company’s decisions and the care that was billed. We stay beside you from the first conversation through the pursuit of a civil recovery.